ROUTE Registry Of the Utilisation of the Transaortic (Tao) TAVI Approach Using the Edwards Sapien XT Valve

NCT ID: NCT01991431

Last Updated: 2017-02-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

303 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an international multi-center, prospective, observational registry with consecutive patient enrollment intended to determine outcome Parameters within 30 days after transaortic transcatheter aortic valve replacement.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this registry is to expand upon existing data sets, to identify patient characteristics and indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic stenosis that are undergoing transaortic transcatheter procedure with the commercially available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ System.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAVI

All Patients undergoing transaortic transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System in participating sites

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Intended transaortic (Tao) TAVI using Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System
* Compliance with the indications according to the Instructions for Use
* Written informed consent

Exclusion Criteria

* Presence of contraindications as to the Instructions for Use
* TAo with concomitant procedure (e.g. Tao + CABG)
* Participation in the SOURCE XT registry
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut für Pharmakologie und Präventive Medizin

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vinayak Bapat, MD

Role: PRINCIPAL_INVESTIGATOR

St. Thomas' Hospital, London, UK

Mauro Romano, MD

Role: PRINCIPAL_INVESTIGATOR

Institut Hospitalier Jacques Cartier, Massy, France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiac Surgery dpt., Innsbruck Medical University Hospital

Innsbruck, , Austria

Site Status

Division of Cardiology, Helsinki University Central Hospital

Helsinki, , Finland

Site Status

CH J. Minjoz - Besancon

Besançon, , France

Site Status

CHU Bordeaux

Bordeaux, , France

Site Status

Hopital Cardio-Vasculaire et Pneumologie Louis Pradel

Lyon, , France

Site Status

Institut Jacques Cartier Massy

Massy, , France

Site Status

CHU Rouen

Rouen, , France

Site Status

CHU Rangueil - Toulouse

Toulouse, , France

Site Status

Robert-Bosch-Hospital Stuttgart

Stuttgart, Baden-Wurttemberg, Germany

Site Status

Städt. Klinikum München GmbH Herzchirurgie Bogenhausen

München, Bavaria, Germany

Site Status

Westdeutsches Herzzentrum Essen - Uniklinikum -

Essen, North Rhine-Westphalia, Germany

Site Status

Universitätsklinikum Kiel - Kardiologie u. Angiologie

Kiel, Schleswig-Holstein, Germany

Site Status

Univ. Padova, Azienda Ospedaliera di Padova

Padua, , Italy

Site Status

Policlinico San Matteo/Department of Cardiac Surgery

Pavia, , Italy

Site Status

Academisch Medisch Centrum

Amsterdam, , Netherlands

Site Status

Rikshospital Oslo

Oslo, , Norway

Site Status

Klinika Kardiochirurgii UCK Gdansk

Gdansk, , Poland

Site Status

St. Thomas Hospital Cardiothoracic surgery dept

London, , United Kingdom

Site Status

James Cook Hospital - Cardiothoracic Division

Middlesbrough, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Finland France Germany Italy Netherlands Norway Poland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Cocchieri R, Petzina R, Romano M, Jagielak D, Bonaros N, Aiello M, Lapeze J, Laine M, Chocron S, Muir D, Eichinger W, Thielmann M, Labrousse L, Rein KA, Verhoye JP, Gerosa G, Bapat V, Baumbach H, Sims H, Deutsch C, Bramlage P, Kurucova J, Thoenes M, Frank D. Outcomes after transaortic transcatheter aortic valve implantation: long-term findings from the European ROUTEdagger. Eur J Cardiothorac Surg. 2019 Apr 1;55(4):737-743. doi: 10.1093/ejcts/ezy333.

Reference Type DERIVED
PMID: 30346515 (View on PubMed)

Romano M, Frank D, Cocchieri R, Jagielak D, Bonaros N, Aiello M, Lapeze J, Laine M, Chocron S, Muir D, Eichinger W, Thielmann M, Labrousse L, Arne Rein K, Verhoye JP, Gerosa G, Baumbach H, Deutsch C, Bramlage P, Thoenes M, Bapat V. Transaortic transcatheter aortic valve implantation using SAPIEN XT or SAPIEN 3 valves in the ROUTE registry. Interact Cardiovasc Thorac Surg. 2017 Nov 1;25(5):757-764. doi: 10.1093/icvts/ivx159.

Reference Type DERIVED
PMID: 28582580 (View on PubMed)

Bonaros N, Petzina R, Cocchieri R, Jagielak D, Aiello M, Lapeze J, Laine M, Chocron S, Muir D, Eichinger W, Thielmann M, Labrousse L, Bapat V, Arne Rein K, Verhoye JP, Gerosa G, Baumbach H, Kofler M, Bramlage P, Deutsch C, Thoenes M, Frank D, Romano M. Transaortic transcatheter aortic valve implantation as a first-line choice or as a last resort? An analysis based on the ROUTE registry. Eur J Cardiothorac Surg. 2017 May 1;51(5):919-926. doi: 10.1093/ejcts/ezw406.

Reference Type DERIVED
PMID: 28369303 (View on PubMed)

Bapat V, Frank D, Cocchieri R, Jagielak D, Bonaros N, Aiello M, Lapeze J, Laine M, Chocron S, Muir D, Eichinger W, Thielmann M, Labrousse L, Rein KA, Verhoye JP, Gerosa G, Baumbach H, Bramlage P, Deutsch C, Thoenes M, Romano M. Transcatheter Aortic Valve Replacement Using Transaortic Access: Experience From the Multicenter, Multinational, Prospective ROUTE Registry. JACC Cardiovasc Interv. 2016 Sep 12;9(17):1815-22. doi: 10.1016/j.jcin.2016.06.031.

Reference Type DERIVED
PMID: 27609256 (View on PubMed)

Bramlage P, Romano M, Bonaros N, Cocchieri R, Jagielak D, Frank D, Bapat V. Transaortic transcatheter aortic valve implantation - rationale and design of the multicenter, multinational prospective ROUTE registry. BMC Cardiovasc Disord. 2014 Nov 1;14:152. doi: 10.1186/1471-2261-14-152.

Reference Type DERIVED
PMID: 25361564 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1149-9900

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

EffecTAVI Registry
NCT05235555 RECRUITING
TAVR Without Predilatation
NCT04350658 UNKNOWN